Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis

Zhao, Zhen; Zhao, Shasha; Ren, Meng; Liu, Ziling; Li, Zhi; Yang, Lei

doi:10.18632/oncotarget.22062

Cited by 37 publications

(32 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One developing area in the management of pulmonary complications, including malignant pleural effusions, is the use of hyperthermic pleural/intrathoracic chemotherapy, following the model used successfully for intraperitoneal management of malignant ascites. A systematic review showed some evidence that this improves symptoms but may influence length of survival in those treated, including breast and ovarian cancer patients . There is additional research into pressurized intrathoracic sprays of chemotherapy, which also shows promise.…”

Section: Changing Patterns In Management Of Symptoms and Timing Of Inmentioning

confidence: 99%

“…A systematic review showed some evidence that this improves symptoms but may influence length of survival in those treated, including breast and ovarian cancer patients. 23 There is additional research into pressurized intrathoracic sprays of chemotherapy, which also shows promise. This option is targeted more toward early palliation when starting initial or second-line therapy and not when managing terminal pulmonary issues.…”

Section: Pulmonary Symptomsmentioning

confidence: 99%

See 1 more Smart Citation

Palliative care in women's cancer care: Global challenges and advances

Cain

Denny

2018

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Women's cancer rates are increasing in low‐ and middle‐income countries, with presentations that are often far advanced requiring intense symptom management, thus advancing the urgent need to address palliative care. Most resource settings have some options available to assist women with advanced gynecologic cancer, and a combination of leveraging these and expanding on emerging models for palliative care could lessen suffering and improve care for women with gynecologic cancers globally. Providing palliative care for women with cancer is constrained by resources (human and physical), lack of equipment, lack of access, and policy absence or barriers. There is important work to be done in advocating for appropriate infrastructure development and legislation to assure that these options are available to women and their families. Access to adequate opioid and other pain relief options for cancer‐related pain is a particular concern given that availability, cost, and legislative prohibitions create barriers that cause suffering for patients and grief for their families who are unable to address their suffering. All of these require ongoing advocacy for continual advances to improve access and infrastructure for palliative care.

show abstract

Section: Changing Patterns In Management Of Symptoms and Timing Of Inmentioning

confidence: 99%

Section: Pulmonary Symptomsmentioning

confidence: 99%

Palliative care in women's cancer care: Global challenges and advances

Cain

Denny

2018

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…Thorough preoperative assessment for chemotherapy-induced toxicity and prehabilitation improve the postoperative outcome and aids in perioperative management. [ 5 ] Chemotherapeutic agents commonly used in HIPEC and HITHOC include cisplatin, doxorubicin, oxaliplatin, and mitomycin C.[ 6 ] These patients can have diminished cardiopulmonary reserve due to the presence of pleural effusion, ascites, or cardiotoxicity from chemotherapeutic agents. The pathophysiological changes in various organs as well as metabolic and electrolyte disturbances are almost similar in HIPEC and HITHOC with a few additional risks related to HITHOC [ Table 3 ].…”

Section: Discussionmentioning

confidence: 99%

Cytoreductive onco-surgery with combined hyperthermic intraperitoneal chemotherapy and hyperthermic intrathoracic chemotherapy: Perioperative challenges

2019

View full text Add to dashboard Cite

“…Only selected patients can benefit from a complete resection, either lungsacrificing surgery (extrapleural pneumonectomy, EPP) or lung-sparing (pleurectomy/decortication, P/D) (11)(12)(13). Surgery can be coupled with intraoperative treatments (14)(15)(16)(17), but a general consensus on the proper multimodality approach is lacking.…”

Section: Mesothelioma Therapies Standardmentioning

confidence: 99%

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

et al. 2020

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the pleural surface associated with asbestos exposure. The median survival of MPM patients is a mere 8-14 months, and there are few biomarkers and no cure available. It is hoped that, eventually, the incidence of MPM will drop and remain low and constant, given that most nations have banned the use of asbestos, but in the meantime, the incidence in Europe is still growing. The exact molecular mechanisms that explain the carcinogenicity of asbestos are not known. Standard therapeutic strategies for MPM include surgery, often coupled with chemotherapy and/or radiotherapy, in a small percentage of eligible patients and chemotherapy in tumors considered unresectable with or without adjuvant radiotherapy. In recent years, several new therapeutic avenues are being explored. These include angiogenesis inhibitors, synthetic lethal treatment, miRNA replacement, oncoviral therapies, and the fast-growing field of immunotherapy alone or in combination with chemotherapy. Of particular promise are the multiple options offered by immunotherapy: immune checkpoint inhibitors, tumor vaccines, and therapies taking advantage of tumor-specific antigens, such as specific therapeutic antibodies or advanced cell-based therapies exemplified by the CART cells. This review comprehensively presents both old and new therapeutic options in MPM, focusing on the results of the numerous recent and ongoing clinical trials in the field, including the latest data presented at international meetings (AACR, ASCO, and ESMO) this year, and concludes that more work has to be done in the framework of tailored therapies to identify reliable targets and novel biomarkers to impact MPM management.

show abstract

Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis

Cited by 37 publications

References 38 publications

Palliative care in women's cancer care: Global challenges and advances

Palliative care in women's cancer care: Global challenges and advances

Cytoreductive onco-surgery with combined hyperthermic intraperitoneal chemotherapy and hyperthermic intrathoracic chemotherapy: Perioperative challenges

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

Contact Info

Product

Resources

About